With over 60 companies currently developing GLP-1 targeting agents ( GlobalData ), the incretin treadmill is running smoothly
doi: 10.1007/s00406-017-0820-z 18 KimM
Appetite suppression begins within the first week at the 2 mg starting dose
doi: 10.3389/fmed.2022.875430 Summary Keywords glucagon-like peptide-1 receptor agonist (GLP-1RA), incretin based therapy, glucose-depent insulinotropic peptide (GIP), dual agonists, tirzepatide, type 2 diabetes Citation Gallwitz B (2022) Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
In This Article: What Is a GLP-1 Diet
What This Program Helps With (Mini-List) Reducing hunger and cravings Supporting measurable weight loss Improving blood sugar stability Preparing patients for bariatric surgery Addressing weight plateaus after bariatric surgery Improving confidence and motivation Reinforcing healthier eating patterns Summary The Medical Weight Loss and GLP-1 Treatment Program provides a safe, structured, individualized pathway for weight loss that stands apart from high-volume, generic treatment models